About Cardiol Therapeutics Inc.
https://www.cardiolrx.comCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
CEO
David G. Elsley
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TEJARA CAPITAL LTD
Shares:2.63M
Value:$2.56M
ADVISORSHARES INVESTMENTS LLC
Shares:557.39K
Value:$543.51K
BANK OF AMERICA CORP /DE/
Shares:551.05K
Value:$537.33K
Summary
Showing Top 3 of 51
About Cardiol Therapeutics Inc.
https://www.cardiolrx.comCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.18M ▲ | $-9.96M ▼ | 0% | $-0.12 ▼ | $-9.94M ▼ |
| Q2-2025 | $0 | $7.68M ▼ | $-8.35M ▼ | 0% | $-0.1 | $-7.65M ▲ |
| Q1-2025 | $0 | $8.43M ▲ | $-8.29M ▼ | 0% | $-0.1 ▲ | $-8.4M ▼ |
| Q4-2024 | $0 | $6.91M ▼ | $-5.68M ▲ | 0% | $-0.12 ▲ | $-5.65M ▲ |
| Q3-2024 | $0 | $14.14M | $-12.73M | 0% | $-0.18 | $-13.94M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $11.62M ▼ | $12.95M ▼ | $3.39M ▼ | $9.56M ▼ |
| Q2-2025 | $18.2M ▼ | $19.94M ▼ | $8.13M ▲ | $11.81M ▼ |
| Q1-2025 | $23.29M ▼ | $25.45M ▼ | $7.87M ▲ | $17.59M ▼ |
| Q4-2024 | $30.58M ▲ | $31.86M ▲ | $7.14M ▲ | $24.73M ▲ |
| Q3-2024 | $15.89M | $17.52M | $7.09M | $10.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.96M ▼ | $-6.93M ▼ | $-3.02K ▲ | $-13.84K ▼ | $-6.57M ▼ | $-6.93M ▼ |
| Q2-2025 | $-8.35M ▼ | $-4.55M ▲ | $-6.44K ▲ | $20.42K ▲ | $-5.1M ▲ | $-4.56M ▲ |
| Q1-2025 | $-8.29M ▼ | $-7.15M ▼ | $-11.94K ▼ | $-13.84K ▼ | $-7.29M ▼ | $-7.17M ▼ |
| Q4-2024 | $-8.18M ▲ | $-5.59M ▲ | $-6.16K ▲ | $18.69M ▲ | $14.7M ▲ | $-5.6M ▲ |
| Q3-2024 | $-12.73M | $-7.77M | $-7.87K | $-4.62K | $-8.14M | $-7.78M |
CEO
David G. Elsley
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TEJARA CAPITAL LTD
Shares:2.63M
Value:$2.56M
ADVISORSHARES INVESTMENTS LLC
Shares:557.39K
Value:$543.51K
BANK OF AMERICA CORP /DE/
Shares:551.05K
Value:$537.33K
Summary
Showing Top 3 of 51